Santhera
Price
Price
Frequently asked questions
What is Santhera's market capitalization?
What is Santhera's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Santhera?
What are the analyst ratings and target price for Santhera's stock?
What is Santhera's revenue over the trailing twelve months?
What is the EBITDA for Santhera?
What is the free cash flow of Santhera?
What is the 5-year beta of Santhera's stock?
How many employees does Santhera have, and what sector and industry does it belong to?
What is the free float of Santhera's shares?
Financials
Market Cap
$116.14M5Y beta
-0.05EPS (TTM)
$6.494Free Float
9.33MP/E ratio (TTM)
1.37Revenue (TTM)
$128.21MEBITDA (TTM)
$65.15MFree Cashflow (TTM)
$53.36MPricing
Analyst Ratings
The price target is $33.86 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
45
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker